The EDGE

The prioritisation of paediatrics and palliative care in cancer control plans in Africa

M S Weaver, A J J Yao, L A Renner, M Harif and C G Lam

Br J Cancer 2015 112: 1845-1856; advance online publication, June 4, 2015; 10.1038/bjc.2015.158

Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study

M M Fidler, C Frobisher, J Guha, K Wong, J Kelly, D L Winter, E Sugden, R Duncan, J Whelan, R C Reulen and M M Hawkins on behalf of the British Childhood Cancer Survivor Study (BCCSS) Steering Group

Br J Cancer 2015 112: 1857-1865; advance online publication, May 19, 2015; 10.1038/bjc.2015.159

Case–control study of Epstein–Barr virus and Helicobacter pylori serology in Latin American patients with gastric disease

M G Cárdenas-Mondragón, J Torres, L Flores-Luna, M Camorlinga-Ponce, R Carreón-Talavera, A Gomez-Delgado, E Kasamatsu and E M Fuentes-Pananá

Br J Cancer 2015 112: 1866-1873; advance online publication, May 21, 2015; 10.1038/bjc.2015.175

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

T Macarulla, A Cervantes, J Tabernero, S Roselló, E Van Cutsem, S Tejpar, H Prenen, E Martinelli, T Troiani, B Laffranchi, V Jego, O von Richter and F Ciardiello

Br J Cancer 2015 112: 1874-1881; advance online publication, May 19, 2015; 10.1038/bjc.2015.144

Translational Therapeutics

Texture analysis of ¹²⁵I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response

V Rajkumar, V Goh, M Siddique, M Robson, G Boxer, R B Pedley and G J R Cook

Br J Cancer 2015 112: 1882-1887; advance online publication, May 19, 2015; 10.1038/bjc.2015.166

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

A Rowland, M M Dias, M D Wiese, G Kichenadasse, R A McKinnon, C S Karapetis and M J Sorich

Br J Cancer 2015 112: 1888-1894; advance online publication, May 19, 2015; 10.1038/bjc.2015.173

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells

F Caiazza, P M McGowan, M Mullooly, A Murray, N Synnott, N O'Donovan, L Flanagan, C J Tape, G Murphy, J Crown and M J Duffy

Br J Cancer 2015 112: 1895-1903; advance online publication, May 26, 2015; 10.1038/bjc.2015.163

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

P F Ferrucci, S Gandini, A Battaglia, S Alfieri, A M Di Giacomo, D Giannarelli, G C Antonini Cappellini, F De Galitiis, P Marchetti, G Amato, A Lazzeri, L Pala, E Cocorocchio and C Martinoli

Br J Cancer 2015 112: 1904-1910; advance online publication, May 26, 2015; 10.1038/bjc.2015.180

Molecular Diagnostics

Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area

K Sideras, S J Bots, K Biermann, D Sprengers, W G Polak, J N M IJzermans, R A de Man, Q Pan, S Sleijfer, M J Bruno and J Kwekkeboom

Br J Cancer 2015 112: 1911-1920; 10.1038/bjc.2015.92

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, D Yang, F Marmorino, G Pasquini, E Sensi, C Lupi, G De Maglio, N Borrelli, S Pizzolitto, G Fasola, R Bertorelle, M Rugge, G Fontanini, V Zagonel, F Loupakis and A Falcone

Br J Cancer 2015 112: 1921-1928; advance online publication, May 5, 2015; 10.1038/bjc.2015.142

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer

A T Alshareeda, O H Negm, A R Green, C C Nolan, P Tighe, N Albarakati, R Sultana, S Madhusudan, I O Ellis and E A Rakha

Br J Cancer 2015 112: 1929-1937; advance online publication, May 19, 2015; 10.1038/bjc.2015.165

PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma

S Beg, A K Siraj, Z Jehan, S Prabakaran, S S Al-Sobhi, M Al-Dawish, F Al-Dayel and K S Al-Kuraya

Br J Cancer 2015 112: 1938-1943; advance online publication, May 19, 2015; 10.1038/bjc.2015.169

Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer

J A Galván, I Zlobec, M Wartenberg, A Lugli, B Gloor, A Perren and E Karamitopoulou

Br J Cancer 2015 112: 1944-1950; advance online publication, May 19, 2015; 10.1038/bjc.2015.177

Genetics and Genomics

Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening

V T Nghiem, K R Davies, J R Beck, M Follen, C MacAulay, M Guillaud and S B Cantor

Br J Cancer 2015 112: 1951-1957; advance online publication, April 28, 2015; 10.1038/bjc.2015.95

NGS-based approach to determine the presence of HPV and their sites of integration in human cancer genome

P Chandrani, V Kulkarni, P Iyer, P Upadhyay, R Chaubal, P Das, R Mulherkar, R Singh and A Dutt

Br J Cancer 2015 112: 1958-1965; advance online publication, May 14, 2015; 10.1038/bjc.2015.121

Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer

T T Seppälä, J P Böhm, M Friman, L Lahtinen, V M J Väyrynen, T K E Liipo, A P Ristimäki, M V J Kairaluoma, I H Kellokumpu, T H I Kuopio and J-P Mecklin

Br J Cancer 2015 112: 1966-1975; advance online publication, May 14, 2015; 10.1038/bjc.2015.160

Letters to the Editor

Comment on: ‘Guidelines for the use of cell lines in biomedical research’: human-to-human cancer transmission as a laboratory safety concern

Y Lazebnik and G E Parris

Br J Cancer 2015 112: 1976-1977; advance online publication, January 13, 2015; 10.1038/bjc.2014.656

Comment on: ‘Evaluation of chemoresponse assays as predictive markers’

C Tian, M J Gabrin, S L Brower and D J Sargent

Br J Cancer 2015 112: 1977-1978; advance online publication, May 19, 2015; 10.1038/bjc.2015.156

Response to Comment on: ‘Evaluation of chemoresponse assays as predictive biomarkers’

E L Korn and B Freidlin

Br J Cancer 2015 112: 1978; advance online publication, May 12, 2015; 10.1038/bjc.2015.157

Comment on: ‘Vitamin D supplements and cancer incidence and mortality: a meta-analysis’

D-Q Jiang, M-X Li, Q-Z Chen and Y Wang

Br J Cancer 2015 112: 1979; advance online publication, March 31, 2015; 10.1038/bjc.2015.117

Comment on: ‘Vitamin D supplements and cancer incidence and mortality: a meta-analysis’

N Keum and E Giovannucci

Br J Cancer 2015 112: 1979-1980; advance online publication, March 31, 2015; 10.1038/bjc.2015.118

Index

Referee Acknowledgement for 2014

Br J Cancer 2015 112: 1981-1988; 10.1038/bjc.2015.210